A novel nonsense mutation (G181X) in the human cholesteryl ester transfer protein gene in Japanese hyperalphalipoproteinemic subjects.

Cholesteryl ester transfer protein (CETP) plays an important role in regulating the concentration and composition of high density lipoprotein (HDL) and low density lipoprotein (LDL). Although several genetic abnormalities causing CETP deficiency have been identified in the Japanese subjects with a marked hyperalphalipoproteinemia (HALP), there are many CETP-deficient subjects for whom the genetic abnormalities have not been clarified. In the present study, we analyzed the molecular basis of an HALP subject without CETP activity and mass, and found a novel mutation in the CETP gene. This novel mutation (G181X) was a G-to-T substitution at codon 181 of exon 6 which replaced a codon for glycine (GGA) with a premature stop codon (TGA). The G181X mutation created a new cutting site by restriction enzyme MaeIII. To estimate the frequency of G181X, we investigated unrelated 294 HALP (HDL-cholesterol > or = 2.59 mmol/L = 100 mg/dl) subjects by restriction fragment length polymorphism (RFLP) analysis with Mae III. One (0.34%) HALP subject was homozygous and four (1.36%) were heterozygous for this mutation. The allelic frequency of a G-to-T substitution at codon 181 of exon 6 was 0.0102 in HALP subjects. From the lipid analysis of the proband and the homozygote, it was clarified that the G181X mutation had dominant effects on HDL and LDL metabolism, similar to a G-to-A substitution at the 5' splice donor site of the intron 14 (1451 + 1G-->A). In conclusion, the G181X mutation is one of causes of HALP in the Japanese HALP subjects, having dominant effects on lipid metabolism.

[1]  S. Yamashita,et al.  Marked hyper-HDL2-cholesterolemia associated with premature corneal opacity. A case report. , 1984, Atherosclerosis.

[2]  A. J. van Rozen,et al.  Cholesteryl ester transfer activity. Localization and role in distribution of cholesteryl ester among lipoproteins in man. , 1984, Atherosclerosis.

[3]  A. Tall,et al.  Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. , 1990, The New England journal of medicine.

[4]  N. Miller,et al.  Pathophysiology of reverse cholesterol transport. Insights from inherited disorders of lipoprotein metabolism. , 1989, Arteriosclerosis.

[5]  S. Yamashita,et al.  Molecular Defect and Atherogenicity in Cholesteryl Ester Transfer Protein Deficiency , 1994, Annals of the New York Academy of Sciences.

[6]  A. Tall,et al.  Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins , 1989, Nature.

[7]  S. Yamashita,et al.  Characterization of plasma lipoproteins in patients heterozygous for human plasma cholesteryl ester transfer protein (CETP) deficiency: plasma CETP regulates high-density lipoprotein concentration and composition. , 1991, Metabolism: clinical and experimental.

[8]  K. Marotti,et al.  Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein , 1993, Nature.

[9]  R. Havel,et al.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. , 1955, The Journal of clinical investigation.

[10]  E. Rubin,et al.  Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. , 1995, The Journal of clinical investigation.

[11]  S. Yamashita,et al.  Very High Density Lipoproteins Induced by Plasma Cholesteryl Ester Transfer Protein (CETP) Have a Potent Antiatherogenic Function a , 1994, Annals of the New York Academy of Sciences.

[12]  酒井 尚彦 Detection of two species of low density lipoprotein particles in cholesteryl ester transfer protein deficiency , 1991 .

[13]  S. Yamashita,et al.  Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. , 1990, The Journal of clinical investigation.

[14]  M. Burstein,et al.  Lipoprotein-polyanion-metal interactions. , 1973, Advances in lipid research.

[15]  G. Franceschini,et al.  Probucol increases cholesteryl ester transfer protein activity in hypercholesterolaemic patients , 1991, European journal of clinical investigation.

[16]  L. Kunkel,et al.  Analysis of human Y-chromosome-specific reiterated DNA in chromosome variants. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Krauss,et al.  Nondenaturing polyacrylamide gradient gel electrophoresis. , 1986, Methods in enzymology.

[18]  H. Mabuchi,et al.  Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. , 1994, The Journal of clinical investigation.

[19]  Y. Matsuzawa,et al.  Determination by the SRID Method of Normal Values of Serum Apolipoproteins (A-I, A-II, B, C-II, C-III, and E) in Normolipidemic Healthy Japanese Subjects , 1986 .

[20]  H. Arai,et al.  Enzyme-linked immunosorbent assay for cholesteryl ester transfer protein in human serum. , 1995, Clinica chimica acta; international journal of clinical chemistry.

[21]  A. Tall Plasma cholesteryl ester transfer protein. , 1993, Journal of lipid research.

[22]  S. Yamashita,et al.  Frequency of exon 15 missense mutation (442D:G) in cholesteryl ester transfer protein gene in hyperalphalipoproteinemic Japanese subjects. , 1995, Atherosclerosis.

[23]  S. Yamashita,et al.  Frequency of intron 14 splicing defect of cholesteryl ester transfer protein gene in the Japanese general population--relation between the mutation and hyperalphalipoproteinemia. , 1993, Atherosclerosis.

[24]  S. Yamashita,et al.  A missense mutation in the cholesteryl ester transfer protein gene with possible dominant effects on plasma high density lipoproteins. , 1993, The Journal of clinical investigation.

[25]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[26]  S. Yamashita,et al.  Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. , 1994, Journal of biochemistry.

[27]  S. Kihara,et al.  Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[28]  S. Yamashita,et al.  Total deficiency of plasma cholesteryl ester transfer protein in subjects homozygous and heterozygous for the intron 14 splicing defect. , 1990, Biochemical and biophysical research communications.

[29]  H. Arai,et al.  Purification, microheterogeneity, and stability of human lipid transfer protein. , 1989, The Journal of biological chemistry.

[30]  S. Yamashita,et al.  Decreased affinity of low density lipoprotein (LDL) particles for LDL receptors in patients with cholesteryl ester transfer protein deficiency , 1995, European journal of clinical investigation.

[31]  Y. Yazaki,et al.  Cholesteryl ester transfer protein deficiency caused by a nonsense mutation detected in the patient's macrophage mRNA. , 1993, Biochemical and biophysical research communications.

[32]  S. Yamashita,et al.  Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. , 1988, The American journal of cardiology.

[33]  山下 静也 Small polydisperse low density lipoproteins in familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activity , 1988 .